Recent advances in therapeutic targeting of the KRAS pathway in cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted inhibition of the rat sarcoma virus (RAS) signaling pathway is a key advance in cancer therapy.
• Kirsten rat sarcoma virus (KRAS) mutations are prevalent in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
• KRAS mutations were historically considered "undruggable" but are now targeted by specific inhibitors.

Purpose of the Study:

• To review recent therapeutic advancements in targeting KRAS mutations.
• To highlight the clinical development of KRAS-specific inhibitors.
• To discuss future strategies for overcoming resistance and improving cancer control.

Main Methods:

• Review of recent scientific literature and clinical trial data.
• Analysis of the efficacy of KRAS inhibitors like Sotorasib, Adagrasib, and Divarasib.
• Exploration of combination strategies and future therapeutic approaches.

Main Results:

• KRAS inhibitors, particularly for KRASG12C and KRASG12D mutations, show promising clinical results.
• Agents like Sotorasib and Adagrasib are effective against KRASG12C mutations, especially in NSCLC.
• Combination therapies have shown improved outcomes, particularly in CRC.

Conclusions:

• Targeting KRAS is a rapidly expanding area in cancer therapeutics with over 50 agents in development.
• Challenges include optimizing clinical trial designs and integrating pharmacodynamic tools for dosing and schedules.
• Future strategies involve combining mutant-specific and mutant-independent approaches to overcome resistance and offer more durable cancer control.